The Los Angeles Times ran an article today by Fran Kritz, Heading to the drugstore? Clip a coupon -- but read the fine print. The article talks about the growing use of retail "coupons" by drug companies anxious to stave off competition, from cheaper ge

On Wed., Nov. 20, as many readied their turkey dinners and packed the car, one Joseph Conn, staff writer for Modern Healthcare, wrote an article detailing the first week of hearings in the Maine prescriber data-mining case.  Little could Mr. Conn know wha

Community Catlayst (PAL's parent organization) and the Alosa Foundation are offering grants as a part of a new campaign called Generics are Powerful Medicine. The goal of Generics are Powerful Medicine is to dispel the unfounded myths surrounding generic

Community Catalyst, a national advocacy organization that builds consumer and community participation in shaping of our health system, has just launched the Generics are Powerful Medicine (GPM) campaign, a grant program to help nonprofits jumpstart creat

Right now, Dr. Daniel Carlat’s article, “Dr. Drug Rep,” is sitting atop the vaunted Most E-mailed list on nytimes.com.  Featured in Sunday’s New York Times Magazine, Dr. Carlat’s narrative recounts his year as a paid speaker for Wyeth Pharmaceuticals and

Then Shakespeare might have enjoyed these 5-minute videos from PharmedOut.  Dubbed “Pharma Insider Parts I and II,” former insider Doug Melnick, MD MPH talks with Pharmed Out’s Adriane Fugh-Berman, MD about off-label prescribing and competitive intelligen

We consider a central part of PAL's mission to be translating the worlds of pharmaceuticals and the law for average consumers. Why does this matter? Because both of these areas, medicines and the law, have a real impact on most people's daily lives. Yet

According to a recent post at Pharma Marketing Blog, online CME has taken a toll on the standard powerpoint and folding chair affairs.  Continuing medical education (CME), which are the credits required for a physician to maintain her medical license, com

Last week, GlaxoSmithKline (NYSE:GSK) filed an antitrust lawsuit against Abbott Laboratories (NYSE:ABT) for Abbott’s 400% price increase for its AIDS drug, Norvir. Strangely, the complaint was filed over three years after PAL coalition member Service Emp